What to expect as the Phase 2 Covid trial unfolds-

Check out the 30 day chartfor IPIX, another fledgling biotech which received FDA fast track approval on 1/14/21 for a Phase 2 Covid-19 trial for Briacilin - moved from .18 on 1/14/21 to .40 at close today. When the word gets out I would expect RVX, to jump nicely.

IPIX has baffled investors for many of the same reasons as RVX - perhaps this opportunity will give RVX long-term investors some short-term cash, hope and staying power to see this get to market. Did DM say revenues?

GLTA

Chicagoest